Companies › Denali Therapeutics
7 active drug programs in 8 registered trials: 6 Phase 1, 2 Phase 2; Neurology, Metabolic and endocrine; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| BIIB122 LRRK2 kinase inhibitor | LRRK2 | Phase 2 | Parkinson Disease | Mar 2027 |
| tividenofusp alfa (DNL310) CNS-penetrant iduronate 2-sulfatase enzyme replacement therapy | IDS | Phase 2 | Mucopolysaccharidosis II | Dec 2027 |
| DNL593 GRN gene modifier | – | Phase 1 | Frontotemporal Dementia | Dec 2026 |
| DNL628 LRRK2 kinase inhibitor | – | Phase 1 | Alzheimer Disease, Early Onset | Feb 2027 |
| DNL952 Pompe disease treatment | – | Phase 1 | Late-onset Pompe Disease | Aug 2028 |
| DNL921 | – | Phase 1 | Alzheimer's Disease | Apr 2030 |
| DNL126 Gene therapy for mucopolysaccharidosis type IIIA | – | Phase 1 | Mucopolysaccharidosis Type IIIA | Jul 2032 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05262023 | DNL593 | Phase 1 | Frontotemporal Dementia | Neurology | Dec 2026 |
| NCT07328451 | DNL628 | Phase 1 | Alzheimer Disease, Early Onset | Neurology | Feb 2027 |
| NCT06602193 | BIIB122 | Phase 2 | Parkinson Disease | Neurology | Mar 2027 |
| NCT05371613 | tividenofusp alfa (DNL310) | Phase 2 | Mucopolysaccharidosis II | Metabolic and endocrine | Dec 2027 |
| NCT07354724 | DNL952 | Phase 1 | Late-onset Pompe Disease | Metabolic and endocrine | Aug 2028 |
| NCT07758595 | DNL921 | Phase 1 | Alzheimer's Disease | Neurology | Apr 2030 |
| NCT04251026 | tividenofusp alfa (DNL310) | Phase 1 | Mucopolysaccharidosis II | Metabolic and endocrine | Feb 2031 |
| NCT06181136 | DNL126 | Phase 1 | Mucopolysaccharidosis Type IIIA | Metabolic and endocrine | Jul 2032 |
Cash and short-term investments of $516m on 2026-09-30; operating cash outflow about $464m a year; runway about 13 months at that burn, to Nov 2027; 1 of 2 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
MediciNova Beijing Suncadia Pharmaceuticals Neuron23 Syntara Solid Biosciences
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.